Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma ScienceNSE:STAR -0.12%65 EV-to-EBITDA is 10.67 as of Jul. 29, 2026, which is 18% above its 10-year median of 9.01. GuruFocus rates NSE:STAR with a GF Score™ of 65/100 and a GF Value™ of ₹762.73 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 744 Drug Manufacturers companies, Strides Pharma Science ranks better than 58.74% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Strides Pharma Science's enterprise value is ₹111,969 Mil.
Strides Pharma Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹10,496 Mil. Therefore, Strides Pharma Science's EV-to-EBITDA for today is 10.67.
The historical rank and industry rank for Strides Pharma Science's EV-to-EBITDA or its related term are showing as below:
NSE:STAR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -452.75 Med: 9.01 Max: 110.94
Current: 10.67
During the past 13 years, the highest EV-to-EBITDA of Strides Pharma Science was 110.94. The lowest was -452.75. And the median was 9.01.
NSE:STAR's EV-to-EBITDA is ranked better than 58.74% of 744
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs NSE:STAR: 10.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Strides Pharma Science's PE Ratio (TTM) for today is calculated as:
Strides Pharma Science's share price for today is ₹1041.70.
Strides Pharma Science's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹60.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's EV-to-EBITDA falls into.
Strides Pharma Science's current Enterprise Value is ₹111,969 Mil.
Strides Pharma Science's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10,496 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a EV-to-EBITDA of 10.67 as of Jul. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Strides Pharma Science. This is 18% above median its historical median of 9.01. According to the industry distribution chart, Strides Pharma Science ranks #307 out of 744 companies in the Drug Manufacturers industry, placing it in the top 41.3%.
Is Strides Pharma Science's EV-to-EBITDA too high?
Strides Pharma Science's current EV-to-EBITDA of 10.67 is 18% above median its 10-year median of 9.01. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Strides Pharma Science's value of 10.67 is 17.8% below this industry median. Based on the distribution chart, Strides Pharma Science ranks #307 out of 744 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #307 out of 744 companies for EV-to-EBITDA. This puts Strides Pharma Science in the upper half of its industry. The industry median EV-to-EBITDA is 12.98. Strides Pharma Science's value of 10.67 is 17.8% below this benchmark. While the company's 10-year median is 9.01 vs. the industry median of 12.98, Strides Pharma Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 744 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current EV-to-EBITDA of 10.67 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Strides Pharma Science. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current EV-to-EBITDA is 10.67, which is 18% above median its own 10-year median of 9.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹762.73, compared to a current price of ₹1,041.70 — trading 36.6% above its estimated fair value. The current EV-to-EBITDA is 10.67, which is 18% above median its 10-year median of 9.01 and 17.8% below the Drug Manufacturers industry median of 12.98. Strides Pharma Science's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current EV-to-EBITDA is 10.67 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,041.70 is trading 36.6% above its estimated GF Value™ of ₹762.73.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
EV-to-EBITDA: 10.67 (18% above median its 10-year median of 9.01)
GF Value™: ₹762.73 vs. price of ₹1,041.70 (36.6% above fair value)
Industry Position: 17.8% below the Drug Manufacturers median (#307 of 744)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
65GF Score
Get the complete analysis for NSE:STAR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
